Taking Out the Trash: A Lab-Made Molecule Cuts Artery Plaque in Half by Switching On the Cell’s Recycling System
A team led by Guido Kroemer screened autophagy-inducing compounds for one that would work across every cell type that matters in artery disease, and settled on 3,4-dimethoxychalcone (3,4-DC). It outperformed spermidine, triethylenetetramine and its own chemical cousin 4,4’-dimethoxychalcone at triggering the cellular recycling machinery in endothelial cells, macrophages and cardiomyoblasts. Injected into two different mouse models of vascular disease, it cut neointimal scarring in surgically grafted veins by about half and reduced aortic plaque burden in fat-fed ApoE-deficient mice by roughly 56 percent. Blood lipids did not change, which points to the drug acting on the vessel wall itself rather than on cholesterol.
Every cell runs a garbage disposal. Autophagy is the process that wraps up damaged proteins, spent mitochondria and surplus lipid droplets and delivers them to the lysosome for breakdown. It slows down with age in almost every tissue, and the decline is now treated as one of the core drivers of cardiovascular aging. The obvious question follows: if you could turn the disposal back on chemically, would arteries stay cleaner?
Kroemer’s group at Gustave Roussy and the Cordeliers Research Centre in Paris has spent a decade chasing that question with a class of compounds they call caloric restriction mimetics, molecules that reproduce some of fasting’s cellular signals without the fasting. Spermidine is the best known. This paper argues that a synthetic chalcone, 3,4-dimethoxychalcone, is a better tool for blood vessels specifically.
The reasoning was practical. Atherosclerosis is not one cell type misbehaving. It involves the endothelial lining, the smooth muscle cells that thicken the vessel wall, and the macrophages that gorge on lipid and turn into foam cells. A compound that induces autophagy in liver cells but not macrophages is not much use here. So the team ran four cell lines side by side, tagged the autophagy marker LC3 with a green fluorescent label, and counted how reliably each candidate produced the telltale pattern of cytoplasmic dots and nuclear clearing. Spermidine and triethylenetetramine were patchy and cell-type dependent. 3,4-DC worked in all four.
Then came the animals. In the first model, surgeons grafted a vein segment into the carotid artery of mice, a procedure that reliably produces the thickened, obstructed vessel seen after human bypass surgery. Some animals also had the compound painted directly onto the outside of the graft in a gel, which is a plausible clinical route for a bypass or a stent. Mice given 3,4-DC kept their vessel lumens open, more than doubling the open channel through the vessel, and had roughly a quarter as many smooth muscle cells piling into the wall. In the second model, mice engineered to develop atherosclerosis were put on a high-fat diet for a month while receiving injections five days a week. Their aortas carried about half the plaque of untreated animals.
The result that gives the story its shape is a negative one. Cholesterol, LDL, HDL and free fatty acids were all unchanged. Whatever 3,4-DC is doing, it is not a statin. The authors read this as evidence for direct action on the vessel wall, most plausibly by helping macrophages digest the lipid they have swallowed and by restraining smooth muscle proliferation.
Two things are worth holding on to. The mechanism is inferred rather than proven, because the experiment that would settle it, deleting autophagy genes and showing the benefit disappears, has not been run. And this is a four-week prevention study in mice, delivered by injection into the abdominal cavity at a dose no human has ever received.
Actionable Insights
There is nothing here to act on directly. 3,4-DC yet, as is not a food component, not a supplement, and not in human trials. Its better-studied cousin 4,4’-dimethoxychalcone, the one found in ashitaba, is a different molecule working through a different pathway (GATA factors rather than TFEB), so ashitaba is not a proxy.
What the paper adds is weight to a principle: autophagy induction protects arteries independently of cholesterol. The magnitudes matter. In fat-fed mice, aortic plaque fell about 56 percent, a standardized effect size (Cohen’s d) near 1.8. In plain terms, roughly 90 percent of treated mice had less plaque than a randomly chosen untreated mouse. In the graft model, wall thickening dropped 50 percent and smooth muscle infiltration 75 percent. Large effects by any convention.
The read-across is to interventions that already exist and share the mechanism: spermidine, caloric restriction or time-restricted eating, and exercise. This paper does not raise or lower the case for any of them. It does suggest that when comparing autophagy inducers, breadth of tissue coverage may matter as much as potency, since spermidine underperformed in exactly the cell types that build plaque.
One caution: a single 3,4-DC injection raised liver and blood triglycerides for 72 hours. The signal disappeared with repeated dosing, but autophagy inducers reshape lipid handling in ways that are not always benign.
Context and Source
Full title: 3,4-dimethoxychalcone induces autophagy and reduces neointimal hyperplasia and aortic lesions in mouse models of atherosclerosis
Open access paper: